Overall, these results indicate that CBP-12 promoted the immunization activity of the antigenic peptide to increase tumor-infiltrating T lymphocytes and induce antigen-specific CD8+ T cell responses in the spleen and dLN targeting B16-OVA tumors, without requiring an adjuvant. This evidence concerns the gene CD8A and neoplasm.